Giada Sebastiani
Overview
Explore the profile of Giada Sebastiani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
164
Citations
2980
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Feng G, Yilmaz Y, Valenti L, Seto W, Pan C, Mendez-Sanchez N, et al.
Liver Int
. 2025 Mar;
45(4):e70058.
PMID: 40062742
Background: This study utilised the Global Burden of Disease data (2010-2021) to analyse the rates and trends in point prevalence, annual incidence and years lived with disability (YLDs) for major...
2.
Feng G, Targher G, Byrne C, Yilmaz Y, Wong V, Lesmana C, et al.
JHEP Rep
. 2025 Feb;
7(3):101271.
PMID: 39980749
Background & Aims: This study used the Global Burden of Disease data (2010-2021) to analyze the rates and trends of point prevalence, annual incidence, and years lived with disability (YLDs)...
3.
Elgretli W, Shengir M, Sasson S, Ramanakumar A, Cinque F, Ballestreros L, et al.
J Viral Hepat
. 2025 Jan;
32(2):e70004.
PMID: 39868661
Steatotic liver disease is prevalent among people with hepatitis C virus (HCV). The new definition of metabolic dysfunction-associated steatotic liver disease (MASLD) emphasises the metabolic drivers of steatosis and recognises...
4.
Pradhan R, Yin H, Lu S, Sebastiani G, Yu O, Suissa S, et al.
Diabetes Care
. 2025 Jan;
48(3):444-454.
PMID: 39774820
Objective: To determine whether glucagon-like peptide 1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 (SGLT-2) inhibitors, separately, compared with dipeptidyl peptidase 4 (DPP-4) inhibitors are associated with a reduced risk...
5.
Riccardo R, Righetti R, Cinque F, Patel K, Sebastiani G
Expert Rev Gastroenterol Hepatol
. 2025 Jan;
19(1):65-80.
PMID: 39772945
Introduction: Accurate and reliable diagnosis and monitoring of hepatic fibrosis is increasingly important given the variable natural history in chronic liver disease (CLD) and expanding antifibrotic therapeutic options targeting reversibility...
6.
Wu C, Targher G, Byrne C, Mao Y, Cheung T, Yilmaz Y, et al.
Am J Gastroenterol
. 2025 Jan;
PMID: 39749919
Introduction: The global burden of metabolic diseases is increasing, but estimates of their impact on primary liver cancer are uncertain. We aimed to assess the global burden of primary liver...
7.
Romano J, Burnside J, Sebastiani G, Ramji A, Patel K, Swain M, et al.
Ann Hepatol
. 2024 Dec;
30(1):101757.
PMID: 39631459
Introduction And Objectives: Prevalence estimates are crucial for enhancing preparedness to prevent and manage chronic diseases. This is the first study to estimate the prevalence of hepatic steatosis and advanced...
8.
Kronfli N, Mambro A, Riback L, Ortiz-Paredes D, Dussault C, Chalifoux S, et al.
Int J Drug Policy
. 2024 Oct;
133:104624.
PMID: 39426103
Background: Patient navigation increases linkage to hepatitis C virus (HCV) care following release from prison; however, little is known about the services patient navigators should provide to maximize linkage to...
9.
Truscello E, Wang S, Young J, Sebastiani G, Walmsley S, Hull M, et al.
J Infect Dis
. 2024 Oct;
231(1):e101-e112.
PMID: 39417816
Background: Both human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infections increase the risk of hepatic steatosis (HS), which in turn contribute to the severity and progression of liver...
10.
Zeng X, Varady K, Wang X, Targher G, Byrne C, Tayyem R, et al.
Metabolism
. 2024 Sep;
161:156028.
PMID: 39270816
Metabolic dysfunction-associated fatty liver disease (MAFLD) or metabolic dysfunction-associated steatotic liver disease (MASLD), has become the leading cause of chronic liver disease worldwide. Optimal dietary intervention strategies for MAFLD are...